Bristol-Myers Squibb Company, a global biopharmaceutical enterprise, has a successful track record of discovering, developing, licensing, manufacturing, marketing, distributing, and selling innovative products to consumers worldwide. With a diverse range of products offered for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases, the company's extensive portfolio includes Eliquis, a reduction inhibitor for the mitigation of stroke/systemic embolism in NVAF and treatment of DVT/PE; Opdivo, an anti-cancer drug; Pomalyst/Imnovid, suited for patients with multiple myeloma; Orencia, ideal for adults with active RA and psoriatic arthritis; and Sprycel, which treats Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also include Yervoy, Empliciti, Abecma, Reblozyl, Opdualag, and Zeposia, making Bristol-Myers Squibb a leader in the biopharmaceutical industry. Bristol-Myers Squibb's diverse product offerings continue to grow with the addition of highly innovative drugs such as Breyanzi, a CD19-directed genetically modified autologous T-cell immunotherapy for the treatment of adults with relapsed or refractory large B-cell lymphoma; Onureg, which treats adult patients with AML; Inrebic, targeted at myelofibrosis; Camzyos, used to treat adults with symptomatic obstructive HCM; Sotyktu, an effective treatment choice for adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory solution for multiple myeloma; and Abraxane, a protein-bound chemotherapy medication. Bristol-Myers Squibb distributes its products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. Founded in 1887 and headquartered in New York, New York, Bristol-Myers Squibb has undergone several name changes and evolved into one of the most reputable biopharmaceutical companies globally.